|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Testing of molecular marker coexpression (EGFR and HER2-neu) improves the estimation of prognosis and appears to define low- and high-risk groups for treatment failure in curatively resected NSCLC.
|
11448895 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We provide evidence of clinical benefit of afatinib in a 50-year-old Asian woman with HER2-mutant NSCLC who previously failed cytotoxic chemotherapy and gefitinib treatment.
|
29215816 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.
|
28478639 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
NSCLC cells which overexpress erbB-2 were more resistant to cisplatin-induced cytotoxicity in comparison to cells expressing low levels of erbB-2.
|
9872333 |
1998 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Using a FDA-approved standardized diagnostic kit, HercepTest, for detection of HER-2/neu in clinical specimens, we examined the expression of HER-2/neu in NSCLCs in archival paraffin-embedded specimens (N = 81).
|
10928158 |
2000 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We retrospectively investigated 88 samples of non-small cell lung cancer (NSCLC) and assessed the correlation between HER2 expression and tumor histology.
|
16080566 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.
|
16825508 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we performed mutational analysis of the ERBB2 kinase domain by polymerase chain reaction-single strand conformation polymorphism assay in 114 non-adenocarcinoma type non-small cell lung cancers (NSCLCs) tissue samples, including 100 squamous cell carcinomas, three adenosquamous carcinomas and 11 large cell carcinomas.
|
16029927 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, respectively.
|
28363995 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, in patients with KRAS wild-type non-small cell lung cancer (NSCLC).
|
24501009 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
|
15447984 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
|
28656214 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The activation of EGFR-HER2 contributes to the acquisition of resistance to pemetrexed in EML4-ALK rearranged non-small cell lung cancer.
|
31795298 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
|
14614004 |
2003 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Future studies in NSCLC need to include immunohistochemistry and fluorescence in situ hybridization analysis to determine the method of choice for evaluating clinically relevant HER2/neu-positive tumors.
|
11894014 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520).
|
20219072 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In vivo, HFI significantly delayed HER2 overexpression of non‑small cell lung cancer (Calu‑3) in human non‑small cell lung cancer xenografts in nude mice, and the inhibition rate was more than 60% (P<0.05) in the group treated with 1 mg/kg the HFI dose; HFI significantly inhibited HER2 expression of breast cancer (FVB/neu) transgenic mouse tumor growth in 1 mg/kg of the HFI dose group, and in the following treatment the 400 mm3 tumors disappeared completely.
|
23258564 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the role of p95HER2 according to HER2 gene copy number (GCN) and HER2 mutation in non-small cell lung cancer (NSCLC).
|
22307009 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
HER2 protein is overexpressed in 20% to 66% of resected NSCLC tumors, and has been shown to predict poor patient outcome in multiple series.
|
11894015 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These considerations suggest that the simultaneous inhibition of EGFR and HER2 may warrant further study in patients with NSCLC.
|
19680294 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that c-erbB2 is a marker of tumour progression in NSCLC which can be observed on protein level and reflects chromosomal alterations at 17q21.
|
11378338 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among the 323 patients with NSCLC (60.1% female; median age, 65 years [range, 33-93 years]), therapeutically targetable mutations were detected in EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF for 113 (35.0%) overall.
|
30325992 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that the significance of HER2 status in NSCLC is different from that in breast cancer because high-grade amplification occurs rarely.
|
12455054 |
2003 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Laboratory methods for assessment of HER2 positivity in NSCLC include immunohistochemistry (IHC) for protein overexpression, fluorescent in situ hybridization (FISH) for gene amplification, and next generation sequencing (NGS) for gene mutations.
|
25601485 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain.
|
17150109 |
2006 |